Download our app Order a test

Helping you to make informed decisions and formulate effective treatment plans

More about RGCC

Information for patients

We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.

More patient information

Cancer tests

New methods and reliable tests to help deliver personalised treatment


RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with a crucial insight into cancer.  The CAMBISeq® – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their […]

View test

Array comparative genomic hybridisation (aCGH) RGCC

The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential […]

View test


Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off. The results of Immune-Frame can be used to analyse the status of a patient’s immune system, and to provide ongoing information about […]

View test

Metastat RGCC

Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location. During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs). Metastat RGCC is […]

View test


ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug. ChemoSNiP analyses a blood sample to identify for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments […]

View test

Onconomics Extracts

Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs). Onconomics Extracts uses three unique and scientifically-proven methods to assess how effective natural treatments are at tackling cancer. The results provide a comprehensive and highly personalised analysis of […]

View test

Onconomics Plus RGCC

Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. During the test, a sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer. Together, the results of the extensive tests […]

View test

Onconomics RGCC

Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments […]

View test

Oncotrail RGCC

Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype. Oncotrail […]

View test

Oncotrace RGCC

Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis. During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their […]

View test

Oncocount RGCC

Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The test is designed as a follow-up test for patients who have cancer and are worried about […]

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & events

Find out more about our latest research, trials and education days

New breast cancer therapy a step closer to clinical trials

An advanced cancer therapy developed by RGCC scientists has been categorised as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA). Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Due to enter clinical trials […]

Read more

Activating p53 protein improves cancer-killing potential

Activating protein p53 can boost a patient’s immune response against cancerous tumours, researchers at Sweden’s Karolinska Institutet have discovered. Using a commercially available substance known as ALRN-6924, the team successfully generated an anti-tumour immune response. The finding improves our understanding of the crucial role p53 plays in tumour development. In the future, it could help […]

Read more

RGCC scientists develop novel new approach to inhibiting SARS-COV-2 replication

RGCC researchers have developed a new approach to tackling COVID-19 (SARS-CoV-2) that could form the basis of a new treatment option. Laboratory tests have established that the new treatments were effective at inhibiting the spread of the disease. The next stage will see them progress to develop a drug delivery system, a further step before […]

Read more

New cancer vaccine effective in 75% of tumours

A new cancer vaccine is 75% effective at eliminating cancerous tumours in mice, say scientists at the University of Konstanz. The combination treatment includes a powerful immunostimulant and a targeted immunotherapy called a cancer checkpoint inhibitor in one dose. Described by the team as a “potent cancer vaccine”, the combination therapy is already being tested […]

Read more

New blood test can diagnose cancer without tumour sample

US scientists have developed the world’s first ‘tumour-uninformed’ test that can detect cancer DNA circulating in the blood of cancer patients following treatment. The liquid biopsy test enables clinicians to test for cancer without needing a sample of tumour tissue. It’s an exciting development and adds yet more evidence to the potential for liquid biopsies […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more